---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-001433"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T02:06:34.633162+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics unveils 2025 milestones; cash runway extended into 2027

## Summary
- Cash, cash equivalents and marketable securities as of Dec 31, 2024 expected to fund operations into 2027.
- Cemsidomide Phase 1 dose escalation in multiple myeloma and NHL to complete in 2H 2025; next-phase studies to start early 2026.
- CFT1946 monotherapy dose escalation in BRAF V600 solid tumors to complete 1H 2025; Phase 1 data in melanoma and CRC expected 2H 2025.
- CFT8919 Phase 1 data from partner Betta in China will inform future development outside China.

## SEC filing metadata
- accession: 0001628280-25-001433
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828025001433/0001628280-25-001433-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828025001433/cccc-20250114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-001433
- JSON: https://secwatch.observer/filing/0001628280-25-001433.json
- Plain text: https://secwatch.observer/filing/0001628280-25-001433.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.